Why licensing authorities need to consider the net value of new drugs in assigning review priorities: Addressing the tension between licensing and reimbursement

McCabe, Christopher, Claxton, Karl orcid.org/0000-0003-2002-4694 and O'Hagan, Anthony (2008) Why licensing authorities need to consider the net value of new drugs in assigning review priorities: Addressing the tension between licensing and reimbursement. International Journal of Technology Assessment in Health Care. pp. 140-145. ISSN 0266-4623

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: Copyright © Cambridge University Press 2007. This is an author produced version of a paper published in International Journal of Technology Assessment in Health Care. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: public health,licensing,cost effectiveness analysis,reimbursement,Medicine (miscellaneous),Health Informatics,Health Information Management,Nursing
Institution: The University of York
Academic Units: The University of York > Economics and Related Studies (York)
Depositing User: Mrs JM Wright
Date Deposited: 25 Jul 2008 10:14
Last Modified: 16 Sep 2016 13:36
Published Version: http://dx.doi.org/10.1017/S0266462308080197
Status: Published
Refereed: Yes
Related URLs:

Downloads

Filename: mccabecj_why_licensing.pdf

Description: mccabecj_why_licensing.pdf

Filename: McCabe_2008_IJTAHC_140-5_final_draft.pdf

Description: McCabe_2008_IJTAHC_140-5_final_draft.pdf

Share / Export